The EGF vaccine (rEGF-p64K/Mont vaccine) is a chemically conjugated peptide-based vaccine jointly developed by BIOTECH PHARMACEUTICAL CO., LTD and Cuba. Commonly referred to as the hu-rEGF-rP64k/Mont vaccine, it consists of a unique combination of two components: 1. Recombinant human epidermal growth factor (hu-rEGF), produced in brewer’s yeast; 2. Recombinant Neisseria meningitidis P64k protein, synthesized in E. coli. These two purified proteins are then cross-linked using glutaraldehyde and further refined through ultrafiltration. The final conjugate formulation is filled into vials under the name hu-rEGF-rP64k/Mont vaccine. When administered, the vaccine triggers a specific active immune response that blocks EGFR-mediated cellular signaling pathways, effectively inhibiting both tumor cell proliferation and the formation of nourishing blood vessels. This process also induces apoptosis (programmed cell death) in cancer cells, ultimately suppressing tumor growth and improving patient survival rates and quality of life. Preclinical studies in animals and clinical trials have demonstrated promising efficacy against malignancies with overexpression of the epidermal growth factor receptor (EGFR), including lung cancer, head and neck cancer, ovarian cancer, and other types of tumors—particularly showing remarkable therapeutic benefits for non-small cell lung cancer. Currently, the vaccine has been approved for use in Cuba, Peru, and Paraguay as a treatment option for advanced-stage non-small cell lung cancer. Additionally, China has completed Phase I clinical trials involving patients with advanced non-small cell lung cancer, and plans are underway to initiate Phase II/III clinical studies.

　　The EGF vaccine (rEGF-p64K/Mont vaccine) is a chemically conjugated peptide-based vaccine jointly developed by BIOTECH PHARMACEUTICAL CO., LTD and Cuba. Commonly referred to as the hu-rEGF-rP64k/Mont vaccine, it consists of a conjugate formed by two key components: 1. Recombinant human epidermal growth factor (hu-rEGF), produced in brewer’s yeast; 2. Recombinant Neisseria meningitidis P64k protein, expressed in E. coli. These two purified proteins are then cross-linked using glutaraldehyde and further refined through ultrafiltration. The resulting conjugate is finally formulated into the hu-rEGF-rP64k/Mont vaccine and filled into vials. Before administration, the vaccine is mixed with Montanide ISA 51 VG mineral oil adjuvant (manufactured by SEPPIC, France) to create an emulsion suitable for injection.
　　
　　This vaccine works by inducing specific active immunity to block EGFR-mediated cellular signaling, thereby inhibiting the growth of both tumor cells and their supporting blood vessels, while also triggering apoptosis (programmed cell death) in tumor cells. As a result, it effectively suppresses tumor progression and treats cancer, ultimately improving patients' survival rates and quality of life. Preclinical studies in animals and clinical trials have demonstrated that this vaccine exhibits remarkable efficacy against malignant tumors with overexpression of the epidermal growth factor receptor (EGFR), including lung cancer, head and neck cancer, ovarian cancer, and others—particularly showing significant therapeutic benefits for non-small cell lung cancer.
　　
　　Currently, it has been approved for marketing in Cuba, Peru, and Paraguay for the treatment of advanced non-small cell lung cancer. A Phase I clinical study involving Chinese patients with advanced non-small cell lung cancer has also concluded, and plans are now underway to initiate Phase II/III clinical trials.